{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:14:21Z","timestamp":1783660461859,"version":"3.55.0"},"reference-count":61,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>This review summarizes the development of an oral inactivated enterotoxigenic Escherichia coli (ETEC) vaccine, ETVAX, describing its progression from preclinical evaluation of vaccine components in animal models to clinical assessment of safety, immunogenicity and, ultimately, protective efficacy in first- and second-generation formulations. Multiple Phase 1 and Phase 2 clinical trials conducted, initially in Swedish adults and subsequently in adults and children in Bangladesh and several African countries (Egypt, Zambia and The Gambia), have shown that the candidate vaccines are well tolerated, safe and capable of inducing robust intestinal or intestine-derived immune responses against the included antigens in most vaccine recipients. ETVAX, developed based on the results gained from studies of the first- and second-generation candidate vaccines, comprises four inactivated E. coli strains engineered to overexpress the most prevalent colonization factors combined with a toxoid and a mucosal adjuvant. Recent trials have shown that ETVAX confers significant protection against moderate\u2013severe ETEC-associated diarrhea in young children in The Gambia and in travelers to Benin in Africa, underscoring its potential value both for endemic populations and travelers.<\/jats:p>","DOI":"10.3390\/microorganisms14071448","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:50:37Z","timestamp":1782867037000},"page":"1448","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ETVAX: From Concepts to Demonstrated Clinical Efficacy"],"prefix":"10.3390","volume":"14","author":[{"given":"Ann-Mari","family":"Svennerholm","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Institute of Biomedicine, Gothenburg University, 45030 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/269602a0","article-title":"Development of improved cholera vaccine based on subunit toxoid","volume":"269","author":"Holmgren","year":"1977","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/iai.13.3.735-740.1976","article-title":"Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin\/toxoid","volume":"13","author":"Svennerholm","year":"1976","journal-title":"Infect. Immun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/iai.21.1.1-6.1978","article-title":"Correlation between intestinal synthesis of specific immunoglobulin A and protection against experimental cholera in mice","volume":"21","author":"Svennerholm","year":"1978","journal-title":"Infect. Immun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(82)91568-9","article-title":"Intestinal antibody responses after immunisation with cholera B subunit","volume":"1","author":"Svennerholm","year":"1982","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/infdis\/149.6.884","article-title":"Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine","volume":"149","author":"Svennerholm","year":"1984","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1128\/JCM.38.1.27-31.2000","article-title":"Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh","volume":"38","author":"Qadri","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.vaccine.2021.04.018","article-title":"Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access","volume":"39","author":"Khalil","year":"2021","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.coi.2005.06.007","article-title":"Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea","volume":"17","author":"Holmgren","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/toxins3091146","article-title":"Modified heat-stable toxins (hSTa) of enterotoxigenic Escherichia coli lose toxicity but display antigenicity after being genetically fused to heat-labile toxoid LT(R192G)","volume":"3","author":"Liu","year":"2011","journal-title":"Toxins"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Begum, Y.A., Baby, N.I., Faruque, A.S., Jahan, N., Cravioto, A., Svennerholm, A.M., and Qadri, F. (2014). Shift in phenotypic characteristics of enterotoxigenic Escherichia coli (ETEC) isolated from diarrheal patients in Bangladesh. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003031"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/0966-842X(96)10068-8","article-title":"Colonization factors of human enterotoxigenic Escherichia coli (ETEC)","volume":"4","author":"Gaastra","year":"1996","journal-title":"Trends Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tim.2023.11.001","article-title":"Colonization factors of human and animal-specific enterotoxigenic Escherichia coli (ETEC)","volume":"32","author":"Svennerholm","year":"2024","journal-title":"Trends Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.3145","article-title":"Identification of enterotoxigenic Escherichia coli (ETEC) clades with long-term global distribution","volume":"46","author":"Connor","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1016\/j.vaccine.2011.06.084","article-title":"A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression","volume":"29","author":"Isidean","year":"2011","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1128\/IAI.72.12.7190-7201.2004","article-title":"Evolutionary and functional relationships of colonization factor antigen i and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli","volume":"72","author":"Anantha","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1016\/j.vaccine.2017.06.006","article-title":"Cross-reactivity and avidity of antibody responses induced in humans by the oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine ETVAX","volume":"35","author":"Leach","year":"2017","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.10.4.569","article-title":"Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli","volume":"10","author":"Wolf","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_18","first-page":"e000121","article-title":"An untypeable enterotoxigenic Escherichia coli represents one of the dominant types causing human disease","volume":"3","author":"Iguchi","year":"2017","journal-title":"Microb. Genom."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Fleckenstein, J.M. (2021). Confronting challenges to enterotoxigenic Escherichia coli vaccine development. Front. Trop. Dis., 2.","DOI":"10.3389\/fitd.2021.709907"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1128\/IAI.66.7.3311-3316.1998","article-title":"Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood","volume":"66","author":"Jertborn","year":"1998","journal-title":"Infect. Immun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1128\/iai.58.2.341-346.1990","article-title":"Roles of different coli surface antigens of colonization factor antigen II in colonization by and protective immunogenicity of enterotoxigenic Escherichia coli in rabbits","volume":"58","author":"Svennerholm","year":"1990","journal-title":"Infect. Immun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/iai.56.2.523-528.1988","article-title":"Role of PCF8775 antigen and its coli surface subcomponents for colonization, disease, and protective immunogenicity of enterotoxigenic Escherichia coli in rabbits","volume":"56","author":"Svennerholm","year":"1988","journal-title":"Infect. Immun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1128\/IAI.00459-07","article-title":"Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh","volume":"75","author":"Qadri","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/infdis\/jiz135","article-title":"Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection Model","volume":"220","author":"Savarino","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0264-410X(89)90228-4","article-title":"Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea","volume":"7","author":"Svennerholm","year":"1989","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/158.2.372","article-title":"Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial","volume":"158","author":"Clemens","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_27","first-page":"1574","article-title":"Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines","volume":"11","author":"Lebens","year":"1993","journal-title":"Biotechnology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0923-2508(90)90137-F","article-title":"Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination","volume":"141","author":"Sanchez","year":"1990","journal-title":"Res. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1574-6968.1988.tb02792.x","article-title":"Synthesis of nontoxic, antibody-binding Escherichia coli heat-stable enterotoxin (STa) peptides","volume":"55","author":"Svennerholm","year":"1988","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0264-410X(97)00169-2","article-title":"Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine","volume":"16","author":"Jertborn","year":"1998","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/S0264-410X(00)00056-6","article-title":"Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children","volume":"18","author":"Qadri","year":"2000","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1086\/314543","article-title":"Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: Results of the initial evaluation in children","volume":"179","author":"Savarino","year":"1999","journal-title":"PRIDE Study Group. J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00006454-200204000-00012","article-title":"Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants","volume":"21","author":"Savarino","year":"2002","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/S0264-410X(03)00077-X","article-title":"Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18\u201336 months of age","volume":"21","author":"Qadri","year":"2003","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.vaccine.2005.08.110","article-title":"Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6\u201317 months of age: Dosing studies in different age groups","volume":"24","author":"Qadri","year":"2006","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1016\/j.vaccine.2007.03.034","article-title":"Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico","volume":"25","author":"Sack","year":"2007","journal-title":"Vaccine"},{"key":"ref_38","unstructured":"Bourgeois, A.L., Halpern, J., Grahek, S., Golub, S., Gustafsson, B., Svennerholm, A.M., Torres, O., Belkind-Gerson, J., Sanchez, D., and Nyquist, I. (2007, January 25\u201327). Vaccination of travellers to Guatemala (GU) and Mexico (MX) with an oral killed vaccine (OKV) for enterotoxigenic E. coli (ETEC): Impact of vaccine \u201ctake\u201d on risk of ETEC disease and infection with enteric pathogens. Presented at the 4th International Conference on Vaccines for Enteric Diseases (VED 2007), Lisbon, Portugal."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/erv.12.12","article-title":"Recent progress toward an enterotoxigenic Escherichia coli vaccine","volume":"11","author":"Svennerholm","year":"2012","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/j.vaccine.2006.12.028","article-title":"Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease","volume":"25","author":"Walker","year":"2007","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.vaccine.2007.12.009","article-title":"Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae","volume":"26","author":"Tobias","year":"2008","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1016\/j.vaccine.2011.09.096","article-title":"Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice","volume":"29","author":"Tobias","year":"2011","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1128\/iai.64.6.2144-2150.1996","article-title":"Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: Potential for use in a broad-spectrum vaccine","volume":"64","author":"Lebens","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e00215-18","DOI":"10.1128\/mSphere.00215-18","article-title":"The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.vaccine.2013.03.027","article-title":"Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA\/I, CS3, CS5 and CS6 combined with a hybrid LT\/CT B subunit antigen, administered alone and together with dmLT adjuvant","volume":"31","author":"Holmgren","year":"2013","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.vaccine.2012.12.063","article-title":"Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA\/I overexpressing bacteria and recombinantly produced LTB\/CTB hybrid protein","volume":"31","author":"Lundgren","year":"2013","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1016\/j.vaccine.2016.04.055","article-title":"Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine","volume":"34","author":"Lundgren","year":"2016","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.vaccine.2013.04.066","article-title":"Different kinetics of circulating antibody-secreting cell responses after primary and booster oral immunizations: A tool for assessing immunological memory","volume":"31","author":"Leach","year":"2013","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1016\/j.vaccine.2018.11.040","article-title":"Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses","volume":"37","author":"Akhtar","year":"2019","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1473-3099(19)30571-7","article-title":"Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: A double-blind, randomised, placebo-controlled phase 1\/2 trial","volume":"20","author":"Qadri","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.vaccine.2021.10.056","article-title":"Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants","volume":"40","author":"Svennerholm","year":"2022","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1016\/j.vaccine.2023.09.052","article-title":"Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX\u00ae) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial","volume":"41","author":"Sukwa","year":"2023","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Hossain, M.J., Svennerholm, A.M., Carlin, N., D\u2019Alessandro, U., and Wierzba, T.F. (2023). A Perspective on the Strategy for Advancing ETVAX\u00ae, An Anti-ETEC Diarrheal Disease Vaccine, into a Field Efficacy Trial in Gambian Children: Rationale, Challenges, Lessons Learned, and Future Directions. Microorganisms, 12.","DOI":"10.3390\/microorganisms12010090"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1473-3099(25)00774-1","article-title":"Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: A double-blind, randomised, placebo-controlled, phase 2b trial","volume":"26","author":"Hossain","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1128\/JCM.00471-07","article-title":"Comparative analyses of phenotypic and genotypic methods for detection of enterotoxigenic Escherichia coli toxins and colonization factors","volume":"45","author":"Wiklund","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e0187024","DOI":"10.1128\/spectrum.01870-24","article-title":"Use of a TaqMan Array Card for identification of enterotoxins and colonization factors directly from stool samples in an enterotoxigenic E. coli vaccine study","volume":"13","author":"Liu","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_57","unstructured":"Mehra, S. (2026). First-of-Its Kind Vaccine that Protects Children from Deadly Intestinal Infections, Scientific American."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"taae008","DOI":"10.1093\/jtm\/taae008","article-title":"Incidence and risk factors for travellers\u2019 diarrhoea among short-term international adult travellers from high-income countries: A systematic review with meta-analysis of cohort studies","volume":"32","author":"Carroll","year":"2025","journal-title":"J. Travel. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"taad045","DOI":"10.1093\/jtm\/taad045","article-title":"Safety and immunogenicity of ETVAX\u00ae, an oral inactivated vaccine against enterotoxigenic Escherichia coli diarrhoea: A double-blinded, randomized, placebo-controlled trial amongst Finnish travellers to Benin, West Africa","volume":"30","author":"Kantele","year":"2023","journal-title":"J. Travel. Med."},{"key":"ref_60","unstructured":"Kantele, A., Jokiranta, T.S., Riekkinen, M., Holmgren, J., Lissmats, A., Sj\u00f6strand, B., Carlin, N., and Svennerholm, A.M. (2025, January 24\u201326). ETVAX\u00ae vaccine against travellers\u2019 diarrhoea among Finnish travellers to West Africa (OEV-123 trial). Proceedings of the Vaccines for Enteric Diseases, Wallenberg Conference Centre, Gothenburg, Sweden."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jpn3.70322","article-title":"Multi-national Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V) Project Working Group. Oral rotavirus vaccine effectiveness among malnourished children in 19 countries: Findings from the MNSSTER-V project","volume":"82","author":"Burnett","year":"2026","journal-title":"J. Pediatr. Gastroenterol. Nutr."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/7\/1448\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:32:45Z","timestamp":1783657965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/7\/1448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["microorganisms14071448"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms14071448","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}